Andrew Hykes - 18 Feb 2023 Form 4 Insider Report for Inari Medical, Inc.

Role: President and CEO, Director
Signature: /s/ Angela Ahmad, attorney-in-fact for Andrew Hykes
Issuer symbol: N/A
Transactions as of: 18 Feb 2023
Net transactions value: +$1,524,050
Form type: 4
Filing time: 22 Feb 2023, 15:54:47 UTC
Previous filing: 24 Jan 2023
Next filing: 14 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NARI	Common Stock	Award	$0	+46,549	+50%	$0.000000	139,595	18 Feb 2023	Direct	F1
transaction	NARI	Common Stock	Sale	$496,710	-9,000	-6.4%	$55.19	130,595	21 Feb 2023	Direct	F2, F3
holding	NARI	Common Stock						1,550	18 Feb 2023	By Child 1
holding	NARI	Common Stock						1,550	18 Feb 2023	By Child 2
holding	NARI	Common Stock						1,550	18 Feb 2023	By Child 3
holding	NARI	Common Stock						1,000	18 Feb 2023	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NARI	Stock Options (Right to Buy)	Award	$2,020,760	+36,085		$56.00	36,085	18 Feb 2023	Common Stock	36,085	$56.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	2023 Annual Restricted Stock Units grant ("RSUs"). Vesting Commencement Date begins January 1, 2023, 1/16th of the RSUs shall vest on each quarterly anniversary of the vesting Commencement Date.
F2	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022.
F3	This transaction was executed in multiple trades at prices ranging from $55.00 to $55.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4	These options were granted on February 18, 2023 under the Inari Medical, Inc. 2020 Incentive Award Plan and are scheduled to become vested and exercisable on a quarterly basis commencing April 1, 2023.